Treatment of resistant chronic central serous chorioretinopathy via platelet-rich plasma with electromagnetic stimulation
In this study, A total of 60 patients diagnosed with PS and met the inclusion criteria were enrolled and randomly divided into two groups. The experimental group population, comprised of 30 patients, received a single dose of PRP while the control group population, also comprised of 30 patients, received a single dose of saline injection, patient reported outcomes were assessed with VAS and ODI scores one week and one month after the injections.
Background: To evaluate whether subtenon injection of platelet-rich plasma (PRP) with retinal electromagnetic stimulation (rEMS) is effective in therapy-resistant chronic central serous chorioretinopathy (CSCR).
Design: Prospective, sequential.
Materials & methods: The study included 22 eyes with resistant chronic CSCR. Cases receiving micropulse laser or additional photodynamic therapy, subtenon PRP, and subtenon PRP + rEMS were classified as times 1, 2 and 3, respectively.
Results: At time 3, the mean bestcorrected visual acuity was 85.7 and 97.0 letters before and after the procedures, respectively (p = 0.01). Submacular thickness improved by 17, 27 and 51% at times 1, 2 and 3 respectively.
Conclusion: For treating resistant CSCR, subtenon PRP + rEMS should be considered as an effective and safe option.